Who
Daniel Barber
President and CEO
Company insider
Files Form 4 as: President and CEO, Aquestive Therapeutics.
In numbers
- Trades disclosed
- 51
- Buys
- 3
- Sells
- 10
- Bought
- $104K
- Sold
- $3.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jul 2018
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $106K25,000 at $4.22 | filing |
| 15 Sep 2026filed 16 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $120K25,000 at $4.82 | filing |
| 15 Sep 2026filed 16 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $121K25,000 at $4.82 | filing |
| 8 Sep 2026filed 9 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $88K91,743 at $0.96 | filing |
| 8 Sep 2026filed 9 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —91,743 at $0.00 | filing |
| 8 Sep 2026filed 9 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —91,743 at $0.00 | filing |
| 8 Sep 2026filed 9 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $88K91,743 at $0.96 | filing |
| 17 Aug 2026filed 18 Aug 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $107K25,000 at $4.29 | filing |
| 17 Aug 2026filed 18 Aug 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $107K25,000 at $4.29 | filing |
| 16 Jul 2026filed 17 Jul 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $82K20,369 at $4.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $81K20,369 at $4.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K4,631 at $4.03 | filing |
| 15 Jul 2026filed 17 Jul 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K4,631 at $4.03 | filing |
| 15 Jun 2026filed 16 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $104K25,000 at $4.16 | filing |
| 15 Jun 2026filed 16 Jun 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $104K25,000 at $4.16 | filing |
| 15 May 2026filed 18 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $35K8,257 at $4.29 | filing |
| 15 May 2026filed 18 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $35K8,257 at $4.29 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $1.4M335,922 at $4.18 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $1.4M335,922 at $4.18 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $754K180,677 at $4.17 | filing |
News
Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares of Stockdailypolitical.com · 16 Sep 2026Critical Survey: Zentalis Pharmaceuticals (NASDAQ:ZNTL) versus Aquestive Therapeutics (NASDAQ:AQST)AQST · tickerreport.com · 21 Oct 2026Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionAQST · rttnews.com · 15 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmAQST · manilatimes.net · 14 Oct 2026
1 headline in the last 90 days name Daniel Barber; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.